To further investigate this molecular heterogeneity, whole sections of the tumor tissue before immunotherapy were selected and sequenced with a small but highly sensitive NGS panel (OncomineTM Colon cfDNA Assay) that includes HotSpot regions of NRAS and KRAS (Table 1). This evidence concerns the gene KRAS and neoplasm.